drugset
drugset / Trial / NCT04375865

Evaluating the Pharmacokinetic Interactions and Safety Between AD-2111 and AD-2112

NCT04375865 ↗

Phase 1 Completed 30 enrolled Addpharma Inc.
Non-randomizedCrossoverSingle-blindTreatment

Summary

A phase I clinical trial to evaluate the pharmacokinetic interactions and safety between AD-2111 and AD-2112

Timeline

Start
2020-05-30
Primary completion
2020-07-16
Completion
2020-07-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 200 mg —
Subject Tramadol Other / unclassified 150 mg —

Indications

No indication recorded.